Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SINGLE-ARM STUDY TO EVALUATE THE SAFETY OF LORLATINIB IN ALK INHIBITOR-TREATED UNRESECTABLE ADVANCED AND/OR RECURRENT ALK-POSITIVE NON-SMALL CELL LUNG CANCER PARTICIPANTS IN INDIA

NCT04541706 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04541706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04541706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SINGLE-ARM STUDY TO EVALUATE THE SAFETY OF LORLATINIB IN ALK INHIBITOR-TREATED UNRESECTABLE ADVANCED AND/OR RECURRENT ALK-POSITIVE NON-SMALL CELL LUNG CANCER PARTICIPANTS IN INDIA
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
August 27, 2020
Completion date
July 20, 2022
Enrollment
100 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer